ImmuPharma plc (LON:IMM – Get Free Report) shares were down 14.6% during trading on Tuesday . The stock traded as low as GBX 3.20 ($0.04) and last traded at GBX 3.20 ($0.04). Approximately 13,200,714 shares changed hands during mid-day trading, a decline of 53% from the average daily volume of 28,314,303 shares. The stock had previously closed at GBX 3.75 ($0.05).
ImmuPharma Stock Performance
The firm has a market capitalization of £10.93 million, a P/E ratio of -262.50 and a beta of 1.53. The stock has a fifty day moving average price of GBX 1.54 and a two-hundred day moving average price of GBX 1.68.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- Financial Services Stocks Investing
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Market Cap Calculator: How to Calculate Market Cap
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Top Biotech Stocks: Exploring Innovation Opportunities
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
